A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine with carboplatin, or bevacizumab (Bev), or bev alone in participants with ovarian cancer (OC). Participants must have confirmation of folate receptor alpha (FRa) positivity by the Ventana folate receptor 1 (FOLR1) Assay. Mirvetuximab Soravtansine (MIRV) is an investigational drug for the treatment of OC. Participants will be assigned to 1 of 3 substudies and further into groups called treatment arms. In substudy 1, arms A-C, participants will receive 1 of 2 doses of MIRV with Bev, or Bev alone. In substudy 2, arms D and E, participants will receive 1 of 2 doses of MIRV with carboplatin, followed by MIRV alone. In substudy 3, arms F and G, participants will receive one of two doses of MIRV with BEV and carboplatin, followed by MIRV with BEV. Approximately 400 participants will be enrolled in the study at 100 sites around the world. Participants will receive intravenously (IV) infused MIRV with IV infused carboplatin, or IV infused Bev, or IV infused carboplatin and Bev, or IV infused Bev alone. The total study duration will be approximately 40 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzenie cech genetycznych nowotworu w próbce tkanki z poprzedniego zabiegu lub nowa biopsja
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu
- •Potwierdzony rak jajnika, wysoko zróżnicowany typ, zaawansowany (Substudy 1 - pierwsza linia) lub wrażliwy na chemioterapię platynową (druga linia)
- •Test genetyczny (BRCA lub HRD) wykonany wcześniej lub gotowość do jego wykonania
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 24, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (78)
UC San Diego Health - Moores Cancer Center /ID# 277574
La Jolla, United States
Sansum Clinic - Solvang /ID# 277712
Solvang, United States
University of Florida College of Medicine /ID# 278348
Gainesville, United States
Orlando Health Cancer Institute Gynecologic Cancer Center - Orlando /ID# 278623
Orlando, United States
Florida Cancer Specialists - North /ID# 278626
St. Petersburg, United States
Florida Cancer Specialists - East /ID# 278605
West Palm Beach, United States
Our Lady of the Lake Physician Group - Medical Oncology /ID# 277440
Baton Rouge, United States
Maine Medical Center - Scarborough Campus /ID# 277205
Scarborough, United States
Karmanos Cancer Institute - Detroit /ID# 277085
Detroit, United States
Intermountain Health - Intermountain Health West End Clinic /ID# 278470
Billings, United States
Md Anderson Cancer Center At Cooper /ID# 278390
Camden, United States
SUNY Upstate Medical University - Syracuse /ID# 277245
Syracuse, United States
FirstHealth of the Carolinas- Speciality Center /ID# 278636
Pinehurst, United States
Jamescare Gynecologic Oncology At Mill Run /ID# 277951
Hilliard, United States
Willamette Valley Cancer Institute and Research Center /ID# 277714
Eugene, United States
Penn Medicine University of Pennsylvania Health System /ID# 277963
Philadelphia, United States
Avera Cancer Institute - Sioux Falls /ID# 278627
Sioux Falls, United States
University Of Tennessee Medical Center /ID# 278225
Knoxville, United States
Texas Oncology - Abilene - Antilley Road /ID# 277739
Abilene, United States
Texas Oncology - Fort Worth Cancer Center /ID# 277989
Fort Worth, United States
Texas Oncology - San Antonio Medical Center - Research Drive /ID# 277735
San Antonio, United States
Texas Oncology - The Woodlands /ID# 277926
The Woodlands, United States
Texas Oncology - Northeast Texas /ID# 277737
Tyler, United States
Virginia Mason Hospital and Medical Center /ID# 277259
Seattle, United States
West Virginia University Hospitals /ID# 278965
Morgantown, United States
St. George Private Hospital /ID# 276570
Kogarah, Australia
Chris O'Brien Lifehouse /ID# 276337
Sydney, Australia
Icon Cancer Centre Wesley /ID# 277199
Auchenflower, Australia
Burnside War Memorial Hospital /ID# 277602
Adelaide, Australia
Icon Cancer Centre Hobart /ID# 277688
Hobart, Australia
Monash Health - Monash Medical Centre - Clayton /ID# 276984
Clayton, Australia
Barwon Health /ID# 277297
Geelong, Australia
Austin Hospital /ID# 276534
Melbourne, Australia
Epworth Hospital - Richmond /ID# 276347
Richmond, Australia
St. John Of God Subiaco Hospital /ID# 277174
Subiaco, Australia
Cliniques Universitaires UCL Saint-Luc /ID# 276321
Brussels, Belgium
AZ Maria Middelares /ID# 276325
Ghent, Belgium
Universitair Ziekenhuis Leuven /ID# 276316
Leuven, Belgium
CHU de Liege /ID# 276500
Liège, Belgium
UCL Namur University Hospital, Site Sainte-Elisabeth /ID# 277183
Namur, Belgium
Masarykuv Onkologicky Ustav /ID# 276080
Brno, Czechia
Vseobecna Fakultni nemocnice v Praze /ID# 276213
Prague, Czechia
Fakultni nemocnice Motol a Homolka /ID# 276300
Prague, Czechia
Herlev Hospital /ID# 276831
Herlev, Denmark
Aalborg University Hospital /ID# 276435
Aalborg, Denmark
Odense University Hospital /ID# 276462
Odense, Denmark
Strasbourg Oncologie Liberale /ID# 276698
Strasbourg, France
Centre Georges Francois Leclerc /ID# 276737
Dijon, France
Centre Francois Baclesse /ID# 276709
Caen, France
Hopital Prive Des Cotes D'Armor /ID# 276706
Plérin, France
Institut Bergonie /ID# 276696
Bordeaux, France
Institut Curie -Site Saint-Cloud /ID# 276850
Saint-Cloud, France
Institut Godinot /ID# 276849
Reims, France
CHU de Limoges site CHU Dupuytren 1 /ID# 276851
Limoges, France
IUCT Oncopole /ID# 276705
Toulouse, France
Centre Antoine-Lacassagne /ID# 276708
Nice, France
Centre Leon Berard /ID# 276710
Lyon, France
Institut du Cancer Avignon Provence - Sainte Catherine /ID# 276692
Avignon, France
Institut Gustave Roussy /ID# 276712
Villejuif, France
National Cancer Center /ID# 276283
Goyang-si, South Korea
Seoul National University Bundang Hospital /ID# 276280
Seongnam-si, South Korea
Seoul National University Hospital /ID# 276182
Seoul, South Korea
Yonsei University Health System Severance Hospital /ID# 276266
Seoul, South Korea
Asan Medical Center /ID# 276955
Seoul, South Korea
Samsung Medical Center /ID# 276261
Seoul, South Korea
Korea University Guro Hospital /ID# 276194
Seoul, South Korea
Hospital Universitario Marques de Valdecilla /ID# 276415
Santander, Spain
Hospital Universitario Donostia /ID# 276404
Donostia / San Sebastian, Spain
Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria /ID# 276438
Las Palmas de Gran Canaria, Spain
Hospital Universitario Virgen del Rocio /ID# 276426
Seville, Spain
Complejo Hospitalario Universitario A Coruna /ID# 276416
A Coruña, Spain
Hospital Universitari Vall d Hebron /ID# 276478
Barcelona, Spain
Hospital Clinic de Barcelona /ID# 276412
Barcelona, Spain
Institut Català D'Oncologia (Ico) - Girona /ID# 276410
Girona, Spain
Clinica Universidad de Navarra - Madrid /ID# 276411
Madrid, Spain
Hospital Clinico San Carlos. /ID# 276407
Madrid, Spain
Instituto Valenciano de Oncología /ID# 276413
Valencia, Spain
Hospital Clinico Universitario Lozano Blesa /ID# 276406
Zaragoza, Spain
Trial contact
ABBVIE CALL CENTER
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.